Theravance Biopharma, Inc.

NasdaqGM:TBPH 株式レポート

時価総額:US$465.7m

Theravance Biopharma 過去の業績

過去 基準チェック /06

Theravance Biopharmaは31.7%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで1.2%毎年増加している。売上は減少しており、年平均6.8%の割合である。

主要情報

31.7%

収益成長率

33.7%

EPS成長率

Pharmaceuticals 業界の成長6.0%
収益成長率-6.8%
株主資本利益率-26.6%
ネット・マージン-78.2%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

Nov 12
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Jul 16
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

収支内訳

Theravance Biopharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:TBPH 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 2463-49660
30 Jun 2462-46650
31 Mar 2462-45680
31 Dec 2357-55700
30 Sep 2355-61710
30 Jun 2351-68710
31 Mar 2349-75680
31 Dec 2251-93670
30 Sep 2252-136720
30 Jun 2252-196770
31 Mar 2254-226870
31 Dec 2155-265990
30 Sep 2159-2661080
30 Jun 2164-2641140
31 Mar 2166-2751130
31 Dec 2072-2951090
30 Sep 2083-2851120
30 Jun 2077-2701100
31 Mar 2088-2471070
31 Dec 1973-2361060
30 Sep 1960-221980
30 Jun 1960-222950
31 Mar 1957-223980
31 Dec 1860-216970
30 Sep 1849-2521010
30 Jun 1841-2601000
31 Mar 1821-2851000
31 Dec 1715-285960
30 Sep 1717-266860
30 Jun 1731-233860
31 Mar 1733-214820
31 Dec 1649-191850
30 Sep 1647-168880
30 Jun 1638-182910
31 Mar 1640-182920
31 Dec 1542-182900
30 Sep 1540-202880
30 Jun 1535-209830
31 Mar 1531-219740
31 Dec 1412-237720
30 Sep 1410-217620
30 Jun 144-203530
31 Mar 141-184480
31 Dec 130-156360

質の高い収益: TBPHは現在利益が出ていません。

利益率の向上: TBPHは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: TBPHは利益を出していないが、過去 5 年間で年間31.7%の割合で損失を削減してきた。

成長の加速: TBPHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: TBPHは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 54.6% ) と比較することは困難です。


株主資本利益率

高いROE: TBPHは現在利益が出ていないため、自己資本利益率 ( -26.61% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘